Onderzoeker
Debby Thomas
- Disciplines:Laboratoriumgeneeskunde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Andere medische en gezondheidswetenschappen, Medische biotechnologie, Ontdekking en evaluatie van geneesmiddelen, Farmaceutica
Affiliaties
- Therapeutische en Diagnostische Antilichamen (Afdeling)
Lid
Vanaf1 jun 2017 → 30 sep 2022 - Gynaecologische Oncologie (Afdeling)
Lid
Vanaf1 mrt 2014 → 31 mei 2017 - Respiratoire Aandoeningen en Thoraxheelkunde (BREATHE) (Afdeling)
Lid
Vanaf1 mrt 2010 → 28 feb 2014
Projecten
1 - 2 of 2
- Symmetrische antilichamen voor symmetrische epitopen: ontwikkeling en validatie van het Symbody platvorm.Vanaf1 okt 2021 → HedenFinanciering: IOF - technologie validatie in labo
- Ontrafeling van de conformatie en oligomerisatie-eigenschappen van proteïne Tau: Aanzet tot innovatieve therapeutische, prognostische en diagnostische strategieënVanaf1 jan 2021 → 31 dec 2023Financiering: IOF - technologie validatie in labo
Publicaties
1 - 10 van 49
- Combined deficient response to polysaccharide-based and protein-based vaccines predicts a severe clinical phenotype(2024)
Auteurs: Rik Schrijvers, Debby Thomas, Giorgia Bucciol, Isabelle Meyts, Xavier Bossuyt
Pagina's: 138 - 149 - Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease(2024)
Auteurs: Debby Thomas, Ilse Hoffman, Erwin Dreesen
Pagina's: 95 - 104 - Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.(2023)
Auteurs: Debby Thomas, Séverine Vermeire
- A yeast-based model to study the structural properties of the neurodegenerative disease-related protein Tau(2023)
Auteurs: Joke Verelst, Sander Govers, Debby Thomas, Joris Winderickx
- A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases(2023)
Auteurs: Wannee Kantasiripitak, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
Pagina's: 896 - 908 - Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn?s disease(2023)
Auteurs: Debby Thomas
Pagina's: 366 - 372 - Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease(2023)
Auteurs: Bram Verstockt, Séverine Vermeire, Debby Thomas, Paul Declerck
Pagina's: 838 - + - Model-informed precision dosing of infliximab to improve outcomes of individual patients with inflammatory bowel diseases(2023)
Auteurs: Wannee Kantasiripitak, Erwin Dreesen, Marc Ferrante, Debby Thomas
- Detection of Breast Cancer-Specific Extracellular Vesicles with Fiber-Optic SPR Biosensor(2023)
Auteurs: Yagmur Yildizhan, Debby Thomas, Nick Geukens, Jeroen Lammertyn, Dragana Spasic
- Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease(2023)
Auteurs: Nathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, Séverine Vermeire, Paul Declerck, Debby Thomas